 | | Vol. 14.38 – 13 October, 2022 |
| |
|
|
| Researchers demonstrated that inhibition of cancer-intrinsic EZH2 promoted antitumor immunity in estrogen receptor a-positive breast cancer.
[Cancer Research] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In human TNBC cell lines and xenograft models, ectopic XBP1s or HSPA5 expression alleviated tumor growth but aggravated cell migration and invasion. These findings uncovered a conserved crosstalk between the Ire1/Xbp1s and Hippo signaling pathways under physiological settings.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers showed that asymmetric Numb partitioning per se was insufficient for the proper control of mammary stem cell dynamics, with differential phosphorylation and functional inactivation of Numb in the two progeny also required.
[Journal of Cell Biology] |
|
|
|
| Scientists identified the zinc finger transcription factor 148 (ZNF148) as a direct target of the MYC proto-oncogene (MYC). ZNF148 suppressed cell proliferation and migration and was transcriptionally repressed by MYC in breast cancer.
[Oncogenesis] |
|
|
|
| Exposure to tinengotinib specifically inhibited proliferation across all subtypes of TNBC in vitro and in vivo, while leaving luminal breast cancer cells intact. Incubation of HCC1806 with tinengotinib led to dose-dependent down-regulation of genes essential for TNBC cell growth and proliferation.
[Molecular Cancer therapeutics] |
|
|
|
| Researchers bioinformatically identified two novel super-enhancer-associated genes – NSMCE2 and MAL2. Through in-vitro pharmacological super-enhancer disruption assays, they confirmed that super-enhancers upregulated NSMCE2 and MAL2 transcriptionally.
[BMC Cancer] |
|  |
|
|
|
| The potential significance of targeting HIF-1α for immunotherapy, chemotherapy, anti-angiogenic therapy, and photodynamic therapy is discussed. The intrinsic mechanism, existing problems and future directions of targeting HIF-1α are also studied.
[Biomedicine & Pharmacotherapy] |
|
|
|
|
| A University of Cincinnati Venture Lab-backed startup has begun developing breast cancer treatment that may be more effective with fewer side effects, thanks to RNA nanotechnology that is similar to what was used to produce COVID-19 vaccines.
[RNA Nanotherapeutics (University of Cincinnatti)] |
|
|
|
|
| November 7 – 9, 2022
Singapore, Singapore |
|
|
|
|
|
| | University of Southern Denmark – Odense, Denmark |
|
|
|
| | University of Colorado Denver – Aurora, Colorado, United States |
|
|
|
| | Italian Institute of Technology – Genoa, Italy |
|
|
|
| | Garvan Institute of Medical Research – Sydney, Australia |
|
|
|
| | University of Illinois Chicago – Chicago, Illinois, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
